One size doesn’t fit all when it comes to prostate cancer risk assessment

A newly published article in the journal Cancer is probably going to drive a number of readers of this blog to distraction — and for any number of good reasons, starting with the idea that all prostate cancer screening either should be or might be discontinued (as suggested by the USPSTF). … READ MORE …

USPSTF on PSA screening … a current update …

The U.S. Preventive Services Task Force (USPSTF) has just issued its “Guide to Clinical Preventive Services” for 2014. The publication (which is available on line) includes summary information about screening for prostate cancer. … READ MORE …

Maybe this time … a real answer to the value of PSA screening?

We have frequently referred to an ongoing trial in the UK known as the ProtecT trial. That trial is comparing the effectiveness and safety of surgery, radiation therapy, active surveillance as treatments for well-characterized men diagnosed with localized prostate cancer … but there is something else important we hadn’t realized … … READ MORE …

“A plea for individualized prostate cancer screening”

For some years, Vickers, Lilja, and their associates have been arguing that baseline PSA level is able to predict long-term risk for prostate cancer, and now a new paper in European Urology seems to provide support for this argument and a practical clinical strategy for its application. … READ MORE …

Shared and emotion-free decision-making with respect to PSA-based screening

The following is (slightly edited) report by Jeffrey J. Tomaszewski, MD, on behalf of UroToday.com, of a state-of-the-art lecture by David Penson, MD, presented at the annual meeting of the American Urological Association (AUA) in Orlando. We hope that UroToday will forgive us for this direct “theft”, but the topic is one of enormous relevance to the patient community. … READ MORE …

Liu and Zoey “are Ferraris” who massively outperform PSA testing

A report on the Medscape Oncology site on Tuesday discussed prostate cancer detection data presented at the annual meeting of the American Urological Association (AUA) by a group of Italian researchers — with the help of two highly trained German Shepherds. … READ MORE …

A 13-year update from the ERSPC screening trial

So one of the presentations given at the recent EAU meeting in Stockholm was an update, by Dr. Jonas Hugosson, at a median 13 years of follow-up, from the European Randomized Study of Screening for Prostate Cancer (ERSPC)  — and there is some good news, but maybe not enough to get carried away by … yet. READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,152 other followers